News

DISCO Pharmaceuticals Welcomes New CEO Mark Manfredi

DISCO Pharmaceuticals Welcomes New CEO Mark Manfredi

DISCO Pharmaceuticals Welcomes New Leadership

Mark Manfredi brings over two decades of international biopharmaceutical industry leadership and cancer drug discovery success to DISCO Pharmaceuticals.

The recent financing will support the development of novel surfaceome-targeted therapies for hard-to-treat tumors.

Mark Manfredi's Appointment as CEO

DISCO Pharmaceuticals, a biopharmaceutical company focused on oncology, recently announced the appointment of Mark Manfredi, Ph.D., as its Chief Executive Officer (CEO). Mark takes over from Roman Thomas, M.D., the company’s founder and previous CEO, who will continue to provide strategic guidance. With this transition, DISCO aims to enhance its innovative approach to cancer treatment.

The Seed Financing Round

Alongside the CEO appointment, DISCO Pharmaceuticals has successfully closed a €36 million seed financing round. This round was co-led by two prominent investors, Ackermans & van Haaren and NRW.Bank, with additional support from investors like Sofinnova Partners, AbbVie Ventures, M Ventures, and Panakes Partners. This funding is crucial for advancing the company's exciting pipeline of surfaceome-targeted drug candidates, especially in the realm of small cell lung cancer and microsatellite-stable colorectal cancer.

Advancement in Cancer Treatments

Mark Manfredi emphasizes DISCO's mission to create differentiated therapies by leveraging its proprietary platform to identify novel cell-surface target pairs. This innovative approach positions DISCO to not only advance existing lead programs but also to expand its treatment pipeline. The focus remains on indication-specific and pan-tumor therapies that hold the potential to significantly impact patient care.

Expertise Behind the Leadership

With over 20 years of experience in the biopharmaceutical industry, Mark has previously held the CEO position at Ikena Oncology and served as an Entrepreneur in Residence at Atlas Venture. His extensive background includes leadership roles at Raze Therapeutics and Takeda Pharmaceuticals, where he played a significant part in developing global oncology R&D strategies.

Innovative Drug Development

DISCO Pharmaceuticals aims to transform cancer treatment through its innovative platform that uncovers previously unknown targets on cancer cell surfaces. As Mark Manfredi steps into the role of CEO, the company is set to harness his expertise in guiding its trajectory toward becoming a leader in surfaceome-guided drug development.

Mark expresses gratitude toward Roman Thomas for his foundational leadership that has brought DISCO to the current pivotal stage in its growth. The next phase under Mark's leadership promises further advancements in the fight against cancer.

About DISCO Pharmaceuticals

DISCO Pharmaceuticals is dedicated to advancing a pipeline of selective, surfaceome-targeted therapies aimed at hard-to-treat tumors. By mapping the entire surface of cells, the company is on the forefront of designing bispecific antibody-drug conjugates (ADCs) and T-cell engagers that offer unprecedented therapeutic specificity and broad efficacy against tumors. This innovative strategy is set to revolutionize the landscape of cancer treatment.

Frequently Asked Questions

Who is the new CEO of DISCO Pharmaceuticals?

Mark Manfredi, Ph.D., has been appointed as the new CEO of DISCO Pharmaceuticals.

How much funding did DISCO Pharmaceuticals recently secure?

DISCO Pharmaceuticals closed a €36 million seed financing round to advance its drug development programs.

What is the focus of DISCO Pharmaceuticals?

DISCO is focused on developing surfaceome-targeted therapies for difficult-to-treat tumors, including small cell lung cancer and colorectal cancer.

What experience does Mark Manfredi bring to DISCO?

Mark has over 20 years of experience in the biopharmaceutical sector, with previous leadership roles in companies like Ikena Oncology and Takeda Pharmaceuticals.

What is unique about DISCO's drug development approach?

DISCO employs a proprietary platform to identify novel cell-surface target pairs, paving the way for groundbreaking cancer therapies.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Mitsubishi's Q3 Sales: SUVs Up, Mirage Out

Updated Category News Views 4

You ever notice how the market treats innovation and tradition like they’re these ever-spinning plates in a circus act? Take Mitsubishi Motors North America (MMNA). Their third-quarter report's got me both nodding in approval and scratching my head. Sure, they sold 18,543 vehicles—down 5.6% from the previous year. But don’t write 'em off just yet. The slumping...

Continue Reading
Maternal Health Index: A New Tool With Big Ambitions

Updated Category News Views 7

A Fresh Take on Maternal Health Today's all about the Heartland Forward's fresh tool, the Maternal Resiliency Index. It's making a splash at the 2026 Heartland Summit with a lot of promise on its shoulders. Backed by economists and health gurus like Emily Oster and Dr. Neel Shah, this index ain't your run-of-the-mill tool. It's here to shake the couch coins out of...

Continue Reading
Nukleus Launches Unified Platform for Athletes' Business

Updated Category News Views 4

Leveling the Business Field for Athletes Athletes spend their lives fighting for every inch on the field, and now Nukleus is giving them the tools to hold ground off it. Why should they be the last ones to know their own business? Ashton Jeanty and Nukleus got tired of that narrative and kicked off a platform today with a real promise: putting an athlete's entire business...

Continue Reading
MiniCo's New Desk: A Game Changer for E&S Market

Updated Category News Views 4

A New Chapter in Industrial Casualty Look out, folks! MiniCo Insurance Agency is making waves with its latest launch. They're teaming up with Lloyd's of London, not to sell fish and chips, but to bring something groundbreaking in the insurance space—an industrial casualty trading desk. And if you’re raising an eyebrow wondering why this matters, let me break it down...

Continue Reading
Ultrabench Revolutionizes AI Model Comparison Game

Updated Category News Views 3

Breaking Down the Messy AI Model Landscape Ultrabench.ai is here to drag AI model comparison out of the dark ages. Picture this: 309 AI models, ranked against a whopping 530 benchmarks, all served up on one plate. If you’re navigating the AI jungle, you’ll realize how Ultrabench is no small fish in this vast ocean. Consolidating Where Others Have Scattered There's a...

Continue Reading
Athlete Threats: Public Info Fuels Security Risks

Updated Category News Views 3

Public Exposure: The New Athlete Achilles' Heel Imagine sitting on millions while living in a glass house. That's the kind of predicament today's athletes find themselves in, thanks to the treasure trove of public information spilling their personal lives all over the internet. According to the latest Hush Intelligence Athlete Threat Report 2026, this very exposure has...

Continue Reading
New Tools Arm Manufacturers in Additive Arena

Updated Category News Views 3

Diving Headfirst into Additive Manufacturing Standards Additive manufacturing (AM)—it's not just another tech buzzword. It's revolutionizing everything from life-saving medical devices to cutting-edge aerospace components. But as with any game-changing innovation, there's a wild west era before standards reign in the chaos. Enter ANSI and America Makes, offering new...

Continue Reading
Wisconsin Chefs Transform Pizza with Crave Brothers Cheese

Updated Category News Views 4

Reimagining Pizza with Wisconsin's Best Cheeses It's not every day you see a pizza challenge that turns a staple of Friday nights into a gastronomic showcase. But that's exactly what's happening in Wisconsin as chefs flex their creativity using Crave Brothers Farmstead Cheese. This is no ordinary cheese-and-pepperoni affair—these culinary pros are cooking up pizzas with...

Continue Reading
Sports Research Joins Costco: Creatine Mix Available

Updated Category News Views 4

Breaking Into the Big League: Sports Research Hits Costco When a company's product finds its way onto Costco's shelves, you know they're not just playing in the minor leagues anymore. This October, Sports Research® made a bold move into the retail giant's sports nutrition section with their new Creatine + Electrolytes powder. It's not their first rodeo when it comes to...

Continue Reading
SaponiQ Reinvents Body Care with Botanical Soap Bars

Updated Category News Views 4

Breaking Through with Simple Innovation I'll be the first to say it's not every day you hear about a soap company trying to shake things up in body care like it’s a tech startup, but here’s SaponiQ taking a wild swing at it with their lineup of botanical cleansing bars. These things are whipped up in their own U.S.-based facility using some fancy cold-process...

Continue Reading

Top 5 Most Recently Viewed Articles

MongoDB's CEO Discusses AI's Current Limitations and Future

Updated Category News Views 170

Understanding AI's Development Within MongoDB MongoDB Inc.'s CEO, Chirantan Desai, has been vocal about the current state of enterprise AI technologies, highlighting that despite the buzz surrounding agentic AI, it remains largely in the pilot phase. As the landscape of technology evolves, the capabilities of AI are frequently discussed, yet Desai emphasizes the need for...

Continue Reading
Evaxion Biotech Modifies ADS Ratio Change Timeline

Updated Category News Views 141

Evaxion Biotech Announces Changes to ADS Ratio Evaxion Biotech A/S (NASDAQ: EVAX), a leader in the TechBio sector focusing on AI-powered vaccines, has made an important announcement regarding the adjustment of the ratio of its American Depositary Shares (ADS) to its ordinary shares. This decision reflects Evaxion's commitment to enhancing investor liquidity as it...

Continue Reading
Mercedes-Benz Faces Economic Hurdles While Preparing New Products

Updated Category News Views 222

Overview of Mercedes-Benz's Current Performance Mercedes-Benz (OTC: MBGAF) has recently shared its financial results for the third quarter, revealing critical insights into its ongoing challenges and strategies. CFO Harald Wilhelm highlighted the company's concerns about its performance amidst a tough macroeconomic climate and significant product transitions. These...

Continue Reading
Marex Group Securities Class Action: Know Your Rights Early

Updated Category News Views 174

Secure Your Rights: Marex Group Securities Class Action Investors, you need to be alert! The Rosen Law Firm, a dedicated advocate for investor rights, is reaching out to assure you of your rights concerning Marex Group plc (NASDAQ: MRX). The firm is highlighting the significance of your actions if you acquired Marex securities within the time frame from May 16, 2024, to...

Continue Reading
Hamilton Zanze Expands Multifamily Portfolio with New Acquisitions

Updated Category News Views 210

Hamilton Zanze Expands Its Multifamily Portfolio Hamilton Zanze, a well-regarded multifamily real estate investment firm headquartered in San Francisco, has recently announced its sponsorship in the acquisition of two significant garden-style communities. These properties, named Lakeview and Sand Pebble/Spanish Oaks, collectively provide 776 apartment homes with diverse...

Continue Reading